FY2024 Earnings Estimate for BIO Issued By Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research increased their FY2024 earnings estimates for Bio-Rad Laboratories in a research note issued on Wednesday, December 18th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $10.20 per share for the year, up from their previous estimate of $10.18. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2024 earnings at $2.79 EPS, Q1 2025 earnings at $2.30 EPS, Q2 2025 earnings at $3.01 EPS, FY2025 earnings at $11.46 EPS and Q1 2026 earnings at $3.09 EPS.

Several other research firms have also issued reports on BIO. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup upped their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada raised their target price on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a report on Monday, December 9th. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Trading Up 0.6 %

Shares of NYSE:BIO opened at $325.94 on Friday. The business’s 50 day simple moving average is $340.91 and its 200 day simple moving average is $322.11. Bio-Rad Laboratories has a 1 year low of $262.12 and a 1 year high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The company has a market capitalization of $9.13 billion, a P/E ratio of -11.93 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the prior year, the business posted $2.33 EPS. The business’s revenue was up 2.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Advisors Ltd. LLC boosted its stake in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. lifted its stake in Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Bio-Rad Laboratories in the third quarter valued at approximately $32,000. Headlands Technologies LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $51,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Bio-Rad Laboratories during the third quarter worth $55,000. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.